
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

January 9, 2007
Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

000-50614
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

13700 Progress Boulevard
Alachua, Florida 32615
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 3.02 Unregistered Sales of Equity Securities.

On January 16, 2007 the Company issued a press release announcing that all of the remaining outstanding \$0.60 warrants issued in connection with its December 2005 private financing had exercised resulting in the issuance of an additional 1,387,500 shares of common stock and proceeds to the Company of \$832,500. The Company had previously announced the acceleration of the Warrants to January 8, 2007. The Company received and deposited the final amounts received as a result of the early expiration of the warrants on January 9, 2007. The sale of shares of common stock upon exercise of the warrants was made in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933. A copy of the press release announcing the exercise of the warrants is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 Other Events.

On January 16, 2007, the Company announced the exercise of the 2005 warrants that were subject to early expiration and the resulting increase in cash associated with the remaining outstanding 2005 warrants being exercised. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Information and Exhibits.**(d) Exhibits.**

<u>Number</u>	<u>Description</u>
99.1	Press Release dated January 16, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

January 16, 2007

ORAGENICS, INC.
(Registrant)

BY: /s/ Robert T. Zahradnik
Robert T. Zahradnik
President and Chief Executive Officer

Oragenics Announces the Exercise of All Outstanding Warrants from December 2005 Private Financing Round**FOR IMMEDIATE RELEASE**

ALACHUA, FL (January 16, 2007) – Oragenics, Inc. (AMEX:ONI) announced today that all outstanding warrants associated with its December 2005 private financing round have been exercised bringing a total of \$832,500 into the company. When combined with existing cash, this additional funding, reduced by a current monthly burn rate estimated at \$160,000, is expected to result in the company having sufficient funding to last through the third quarter 2007.

Dr. Robert Zahradnik, Oragenics' president and CEO stated, "We appreciate the confidence and support for the company expressed by the December 2005 warrant holders. On a fully diluted basis, the exercise of these warrants has caused no additional dilution to current shareholders, and will help fund our development programs, including our novel antibiotic, MU1140™, and the IVIAT™ technology recently obtained as part of the iviGene acquisition." Additional funding will be necessary to further exploit all of the product opportunities currently under development and to continue the company's operations in the future.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas: infectious disease and oncology. Oragenics' core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections and obesity. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to fund our future operations and successfully develop and commercialize products using the iviGene proprietary technologies and those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Robert T. Zahradnik, 386-418-4018 X222
www.oragenics.com